Loading…
← CockpitCompetitor Analysis › 6872.HK TenNor Therapeutics Suzhou Ltd. Class HOpen in the cockpit ↗

TenNor Therapeutics Suzhou Ltd. Class H6872.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Mkt cap
$470M
US dollars, full cap
Free float
12%
of shares outstanding
$/day
$846,203
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · HKDHK$69.30
1D+2.1%
1W-4.3%
1M-32.8%
3M-61.5%
6Mn/a
YTDn/a
1Yn/a
ATR %11.1%
52w lowhigh75.8% off high

What TenNor Therapeutics Suzhou does

Employees: 54

TenNor Therapeutics Suzhou at a glance

Size TenNor Therapeutics Suzhou (6872.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $470M, the 763rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$69.30 on 18 Nov 2026.

TenNor Therapeutics Suzhou financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenuen/aHK$0HK$0HK$0
Revenue growth————
Gross profitn/a-HK$1.72M-HK$2.92M-HK$3.19M
EBITDAn/a-HK$129M-HK$87.0M-HK$138M
Net incomen/a-HK$166M-HK$158M-HK$212M
Free cash flown/a-HK$96.4M-HK$55.0M-HK$111M
Capital expendituren/aHK$491,289HK$220,097HK$566,864
Total debtn/aHK$31.9MHK$1.05BHK$910M

Quarterly statements and history in the cockpit →

TenNor Therapeutics Suzhou competitors and peer comparison

How TenNor Therapeutics Suzhou compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TenNor Therapeutics Suzhou against its 20 peers (data as of 18 Nov 2026)
Measure6872.HKPeer medianRank in peer set
1-month return-32.8%-9.5%2nd lowest of 21
Distance from 52-week high-75.8%-41.1%3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%

Questions

Which companies are TenNor Therapeutics Suzhou's closest peers?
The cockpit's peer set: Fennec Pharmaceuticals (FENC), Kamada (KMDA), DiaMedica Therapeutics (DMAC), HanchorBio (7827.TW), Neurogene (NGNE), Monopar Therapeutics (MNPR), TaiMed Biologics (4147.TWO), Crescent Biopharma (CBIO).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.